Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Retatrutide is the first triple agonist (GLP-1, GIP, glucagon) to reach Phase 3 clinical trials for obesity
altRx does not provide medical services, does not employ healthcare providers, does not participate in clinical decisions, and does not practice medicine
Pharmaceutical companies will need partners capable of supporting lower-volume, higher-mix production environments, managing packaging transfers and enabling rapid market entry in tightly regulated conditions
Take it as soon as you remember, unless its almost time for your next dose
Tirzepatide (Zepbound) is available now with strong efficacy and a well-established safety profile
US$ 25.57
US$ 20.56
US$ 25.45
US$ 27.19
US$ 20.52
